Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir

Journal of Hepatology

Volumn 54, Issue 3, 2011, Pages 449-454

  Reijnders, Jurriën G P ^a   Rijckborst, Vincent ^a   Sonneveld, Milan J ^a   Scherbeijn, Sandra M J ^a   Boucher, Charles A B ^a   Hansen, Bettina E ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Entecavir; Hepatitis B; Peginterferon; Quantitative HBsAg

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON TYPE I; KINETICS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 79951669706     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.07.046     Document Type: Article

References (19)

1. J.L. Dienstag Hepatitis B virus infection The New Engl J Med 359 14 2008 1486 1500
2. B. Werle-Lapostolle, S. Bowden, S. Locarnini, K. Wursthorn, J. Petersen, and G. Lau Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 7 2004 1750 1758 (Pubitemid 38736340)
3. K. Wursthorn, M. Lutgehetmann, M. Dandri, T. Volz, P. Buggisch, and B. Zollner Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B Hepatology (Baltimore, Md) 44 2006 675 684 (Pubitemid 44433724)
4. H.L. Chan, V.W. Wong, A.M. Tse, C.H. Tse, A.M. Chim, and H.Y. Chan Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response Clin Gastroenterol Hepatol 5 12 2007 1462 1468 (Pubitemid 350181604)
5. J.J. Sung, M.L. Wong, S. Bowden, C.T. Liew, A.Y. Hui, and V.W. Wong Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy Gastroenterology 128 7 2005 1890 1897 (Pubitemid 40824700)
6. J.J. Feld, D.K. Wong, and Heathcote.E.J. Endpoints Endpoints of therapy in chronic hepatitis B Hepatology (Baltimore, Md) 49 2009 S96 S102
7. M.R. Brunetto, F. Moriconi, F. Bonino, G.K. Lau, P. Farci, and C. Yurdaydin Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology (Baltimore, Md) 49 2009 1141 1150
8. E.K. Manesis, E.S. Hadziyannis, O.P. Angelopoulou, and S.J. Hadziyannis Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels Antiviral therapy 12 1 2007 73 82 (Pubitemid 46340428)
9. R. Moucari, V. Mackiewicz, O. Lada, M.P. Ripault, C. Castelnau, and M. Martinot-Peignoux Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients Hepatology (Baltimore, Md) 49 2009 1151 1157
10. V. Rijckborst, M.J. Ter Borg, Y. Cakaloglu, P. Ferenci, F. Tabak, and M. Akdogan A randomized trial of peginterferon alfa-2a with or without ribavirin for HBeAg-negative chronic hepatitis B Am J Gastroenterol 105 8 2010 1762 1769
11. H.L. Janssen, M. van Zonneveld, H. Senturk, S. Zeuzem, U.S. Akarca, and Y. Cakaloglu Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 9454 2005 123 129 (Pubitemid 40091801)
12. S.D. Pas, E. Fries, R.A. De Man, A.D. Osterhaus, and H.G. Niesters Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays J Clin Microbiol 38 8 2000 2897 2901 (Pubitemid 30640570)
13. E.H. Buster, H.J. Flink, Y. Cakaloglu, K. Simon, J. Trojan, and F. Tabak Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b Gastroenterology 135 2 2008 459 467
14. S. Pocock Clinical trials: a practical approach 1983 Wiley New York
15. M. Kohmoto, M. Enomoto, A. Tamori, D. Habu, T. Takeda, and N. Kawada Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers J Med Virol 75 2 2005 235 239 (Pubitemid 40053734)
16. M. Peters Actions of cytokines on the immune response and viral interactions: an overview Hepatology (Baltimore, Md) 23 1996 909 916 (Pubitemid 26112009)
17. I.C. Wu, C.L. Lai, S.H. Han, K.H. Han, S.C. Gordon, and Y.C. Chao Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage Hepatology (Baltimore, Md) 51 2010 1185 1189
18. E.H. Buster, B.E. Hansen, G.K. Lau, T. Piratvisuth, S. Zeuzem, and E.W. Steyerberg Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa Gastroenterology 137 6 2009 2002 2009
19. R.N. Chien, Y.F. Liaw, and M. Atkins Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian hepatitis lamivudine trial group Hepatology (Baltimore, Md) 30 1999 770 774 (Pubitemid 29409422)